If you were one of the prescient investors who understood the merit of Moderna (NASDAQ: MRNA) before its impressive (and rapid) work on the coronavirus vaccine, congratulations! As a (formerly) longtime Moderna skeptic, my wariness remained strong, even throughout its vaccine development work last year. The mid-2010s were not a great time for Moderna.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting